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 Hepatocellular carcinoma (HCC) is a heterogeneous disease in terms of etiology, 
morphology, biological behavior, response to treatment, and clinical outcome. Efforts have 
been made on classifying HCCs according to the status of gene mutations, chromosomal 
aberrations, gene/protein expression, and epigenetic modification in order to find hidden 
molecular features that can explain this heterogeneity [1, 2]. The recent advances in 
molecular classification and the re-emergence of a cancer stem cell (CSC) hypothesis have 
highlighted the central role of stemness in HCC pathogenesis [3]. Moreover, sorafenib 
increased overall survival in a randomized controlled trial against placebo in advanced 
HCC, and tumor progression invariably occurred. Deciphering the underlying mechanism 
of stemness acquisition in liver cancer cells is a major issue because stemness contributes to 
tumor chemo and radio-resistance, two key features of HCC [4].  
Epithelial Cell Adhesion Molecule (EpCAM/CD326) is a type 1 transmembrane protein 
that can antagonize cadherin-mediated cell to cell adhesion [5], and is one of the first tumor 
associated antigens identified [6]. Although EpCAM is known to be expressed in a variety 
of normal epithelial cells, it is strongly overexpressed in human adenocarcinomas [7]. In 
liver cell lineages, EpCAM is absent in mature hepatocytes but detectable in hepatic 
stem/progenitor cells and cholangiocytes [8]. Numerous studies have suggested the utility 
of EpCAM as a marker to identify liver cancer stem cells as well as normal hepatic 
progenitors [3]. In HCC, EpCAM-positivity correlates with a high frequency of vascular 
invasion, poor prognosis after surgical resection, and high infection rates with hepatitis B 
virus (HBV) [9]. Gene signatures of EpCAM-positive HCC have demonstrated an 
activation of stemness-related genes together with Wnt signaling pathway. EpCAM is 
reported to be one of the Wnt signaling target genes in HCC [10]. More recently, EpCAM 
is identified as one of the “cell surface to nuclear missile” that activates Wnt signaling 
pathway by its intracellular domain (ICD) cleaved by γ-secretase [11]. However, it is 
unclear why the presence of EpCAM-positive HCC cells is more frequent in HBV-related 
HCCs than HCV-related or non-B non-C HCCs and if the virus itself could induce an 
EPCAM-mediated Wnt activation. 
In this issue of Journal of Hepatology, Mani and colleagues proposed the potential clues 
that explain the liaison between EpCAM expression, Wnt signaling activation, and cancer 
stemness in HCC [12]. First, using two different HBV replication/infection cell lines 
HepAD38 and HepG2-NTCP, they identified an increase of EpCAM ICD (EpICD) and 
decrease of full length EpCAM that induces the activation of Wnt signaling pathway in 
HBV replicating/infected cells. This protein modification was attenuated by γ-secretase 
inhibitor DAPT, suggesting that EpCAM undergoes regulated intramembrane proteolysis 
(RIP) by γ-secretase in HBV replicating/infected cells.  
Next the authors explored the role of SUZ12, a protein of the Polycomb Repressive 
Complex 2 (PRC2) that regulates open/close chromatin status. According to their previous 
findings, HBV X (HBx) protein induced the degradation of SUZ12 by the proteasome [13, 
14]. SUZ12 knockdown as well as HBx expression resulted in the induction of EpCAM 
gene/protein together with the activation of canonical Wnt signaling pathway and stemness-
related genes encoding NANOG, OCT4, and SOX2. As expected, an isolated subset of 
HBV replicating cells showed an activation of the canonical Wnt signaling and of the 
stemness-related genes, that promotes chemoresistance to sorafenib and cisplatin. 
Activation of EpCAM and stemness-related genes with downregulation of SUZ12 in HBV-
related HCC was further supported in vivo in HBx/c-Myc transgenic mice model. Thus, 
their data illustrated the role of PRC2 suppression by HBx that induces stemness in cancer 
cells through chromatin modifications and activation of imprinted genes. Induction of 
EpCAM together with the RIP by γ-secretase resulted in the activation of EpCAM and Wnt 
signaling pathways. 
Mani and colleagues then took advantage of gene sets analysis (hCSC-like gene signature) 
derived from their EpCAM RIP analysis in HBV-related HCC. They sub-classified HCCs 
according to this gene signature in two independent cohorts, and confirmed the prognostic 
values of the hCSC-like gene signature in HCC. Importantly, CTNNB1 mutations, which 
resulted in the activation of canonical Wnt signaling, were not detected in hCSC-like HCCs. 
Intriguingly, these data were consistent with previous genomic studies suggesting the 
existence of two different types of Wnt signaling activation in HCC according to the 
presence of CTNNB1 mutation or not (Figure 1) [1]. Somatic CTNNB1 (coding for β-
catenin) mutations have been described in 20 to 40% of HCC [1]. These mutations impair 
the degradation of β-catenin by the proteasome and promote its translocation in the nucleus 
and the expression of hepatocyte-related Wnt-target-genes such as GLUL and LGR5. 
Interestingly, these tumors belong to a homogeneous molecular subtype associated with 
histological features (well differentiated tumor with cholestasis) and etiology (hepatitis C 
virus infection) [1] Furthermore, this HCC subtype frequently exhibited the uptake of the 
contrast reagent gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-
DTPA), known to be metabolized in hepatocytes and secreted into bile, in the hepatobiliary 
phase of magnetic resonance imaging (MRI), consistent with their cholestatic feature [15, 
16]. In contrast, a second subgroup of HCC without CTNNB1 mutations harbored Wnt 
activation with induction of other Wnt target genes (such as MYC and CCND1) together 
with stem cells features and TGF beta pathway upregulation [17]. This subclass of tumors 
is associated with a poor prognosis and a high rate of HBV related HCC. 
This study has several implications in terms of mechanistic insights about the development 
of HCC with stem cell features and its treatment strategy. First, this study suggests that 
HBx protein may activate stemness-related genes through chromatin modifications by 
PRC2 repression, EpCAM RIP activation, and Wnt signaling activation. Because the 
simple canonical Wnt signaling activation by CTNNB1 mutations did not enhance the 
stemness-related genes, one can speculate that HBV infection together with HBx and 
EpCAM protein expression may somehow erase the epigenetic memories to reprogram the 
cell fate of infected hepatocytes (Figure 1). It is unclear if complete eradication of HBV 
including HBx, cccDNA, and minichromosome can restore the epigenetic memories of 
infected hepatocytes or HCC cells.  
Because γ-secretase activity may regulate Notch signaling as well as EpCAM RIP and 
cadherin, it is possible that other signaling pathways such as Notch signaling pathway may 
also play a role in the induction of stemness in HBV-related HCC. Exploration of γ-
secretase activation mechanism may provide important clues to understand the “cell surface 
to nuclear missile” signaling in HCC in the future.  
Second, this study identifies potential therapeutic targets such as Wnt, γ−secretase, and 
PRC2 in HBV-related HCC with stem cell features. Unfortunately, no US Food and Drug 
Administration (FDA)-approved drugs are available that can target these pathways [18], 
and further efforts are required to provide new treatment for patients with HCC harboring 
stem cell features. 
A potential limitation of this study is that the main conclusion was drawn from the 
experimental data of HCC cell lines and not of untransformed hepatocytes. It is still unclear 
if epigenetic reprogramming occurs in HBV-infected normal hepatocytes and 
stem/progenitor cells, when epigenetic reprogramming starts after HBV infection, and how 
frequently such epigenetic reprogramming can affect the cellular phenotypes in normal 
liver lineages. Further studies are required. 
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Figure Legend 
Fig. 1. HBx and induction of HCC stemness.  
Accumulation of HBx results in the degradation of SUZ12, suppression of the PRC2 
function and leads to epigenetic reprogramming and activation of hCSC genes and 
imprinted genes including EPCAM. EpCAM then undergoes RIP by γ-secretase and 
induces Wnt-target-genes such as CCND1 and MYC. In contrast, CTNNB1 mutations result 
in the nuclear accumulation of β-catenin without affecting epigenetic reprograming, and 
activate hepatocyte-related Wnt-target-genes such as GLUL and LGR5.  
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